Antibody Drugs

Antibody Drugs includes companies developing monoclonal antibodies or related antibody-based therapeutics. These assets are central to many oncology, immunology, and rare-disease franchises because they can offer target specificity and scalable biologic development paths.

Why watch Antibody Drugs

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Antibody Drugs news

The latest feed items from companies currently grouped under Antibody Drugs.

1. 01
   2026-11-05 21:01 EST

   CRVSCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results

   Source: Corvus Pharmaceuticals

2. 02
   2026-11-05 15:08 EST

   GSKGSK showcases progress in liver portfolio at AASLD 2026

   Source: GSK plc

3. 03
   2026-11-04 14:01 EST

   CRVSCorvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition

   Source: Corvus Pharmaceuticals

4. 04
   2026-11-04 14:00 EST

   LEGNLegend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

   Source: Legend Biotech Corporation

5. 05
   2026-11-03 12:00 EST

   IFRXInflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

   Source: Inflarx NV

6. 06
   2026-11-02 21:05 EST

   REGNRegeneron Announces Investor Conference Presentations

   Source: Regeneron Pharmaceuticals

7. 07
   2026-11-02 14:00 EST

   CMPXCompass Therapeutics to Participate in Upcoming November Investor Events

   Source: Compass Therapeutics

8. 08
   2026-10-30 10:30 EST

   REGNRegeneron Reports Third Quarter 2026 Financial and Operating Results

   Source: Regeneron Pharmaceuticals

9. 09
   2026-10-29 12:00 EST

   CRVSCorvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026

   Source: Corvus Pharmaceuticals

10. 10
    2026-10-28 07:00 EST

    GSKGSK delivers strong Q3 performance and continued momentum

    Source: GSK plc

11. 11
    2026-10-28 06:00 EST

    RHHBYRoche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

    Source: Roche Holdings AG

12. 12
    2026-10-27 12:00 EST

    LEGNLegend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

    Source: Legend Biotech Corporation

13. 13
    2026-10-27 11:30 EST

    IFRXInflaRx Announces November Investor Events

    Source: Inflarx NV

14. 14
    2026-10-27 06:00 EST

    RHHBYRoche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

    Source: Roche Holdings AG

15. 15
    2026-10-26 15:30 EST

    GSKRis-Rez reduced risk of disease progression or death by 67% versus chemotherapy in patients with relapsed osteosarcoma in China

    Source: GSK plc

16. 16
    2026-10-26 11:00 EST

    REGNRegeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

    Source: Regeneron Pharmaceuticals

17. 17
    2026-10-25 15:30 EST

    RHHBYRoche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

    Source: Roche Holdings AG

18. 18
    2026-10-25 09:15 EST

    REGNLibtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

    Source: Regeneron Pharmaceuticals

19. 19
    2026-10-24 23:00 EST

    GSKJemperli (dostarlimab) data show 76% of patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response

    Source: GSK plc

20. 20
    2026-10-24 08:15 EST

    CMPXCompass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

    Source: Compass Therapeutics

Companies in Antibody Drugs

18 companies tagged with Antibody Drugs.

Frequently Asked Questions